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Abstract 
Large neutral amino acid transporter 1 (LAT1, SLC7A5) is abundantly expressed in various 
types of cancer, and it has been thought to assist cancer progression through its activity for 
uptake of neutral amino acids. However, the roles of LAT1 in renal cell carcinoma (RCC) 
prognosis and treatment remain uncharacterized. Therefore, we first retrospectively examined 
the LAT1 expression profile and its associations with clinical factors in RCC tissues (n=92). The 
results of immunohistochemistry showed that most of the tissues examined (92%) had cancer-
associated LAT1 expression. Furthermore, the overall survival (OS) and progression-free 
survival (PFS) were shorter in patients with high LAT1 expression levels than in those with low 
LAT1 expression levels (P = 0.018 and 0.014, respectively), and these associations were further 
strengthened by the results of univariate and multivariate analyses. Next, we tested the effects of 
JPH203, which is a selective LAT1 inhibitor, on RCC-derived Caki-1 and ACHN cells. It was 
found that JPH203 inhibited the growth of these cell types in a dose-dependent manner. 
Moreover, JPH203 clearly suppressed their migration and invasion activities. Thus, our results 
show that LAT1 has a great potential to become not only a prognosis biomarker but also a 
therapeutic target in RCC clinical settings. 
Introduction 
Renal cell carcinoma (RCC), of which the most prevalent type is clear cell RCC, is a 
common cancer that accounts for approximately 3.8% of all new cancer cases, and more than 
140,000 people worldwide die from RCC every year. (1) RCC has a poor clinical outcome 
because 20–30% of the patients already have distant metastasis at the time of diagnosis, and 25–
40% of RCC patients treated with nephrectomy eventually have relapse or distant diseases. (2) 
The frequency of 5-year survival rate of metastatic RCC is only 23%. (3) 
Two prognostic models have been widely used to obtain clues for prediction of the 
clinical course and determination of the therapeutic approach for metastatic RCC: the Memorial 
Sloan Kettering Cancer Center model and the International Metastatic Renal Cell Carcinoma 
Database Consortium model. However, there is currently no clinically useful prognostic marker 
for RCC including non-metastatic RCC. Clinicians must therefore determine how to follow-up 
postoperative patients without any objective guidelines. (4) Therefore, identification of a useful 
prognostic marker for RCC is needed to improve overall clinical results for RCC. 
One of the reasons for the poor survival rate of patients with metastatic RCC has 
been the lack of effective drugs. However, molecularly targeted drugs and, more recently, 
immune checkpoint inhibitors have been approved and have contributed to the improvement of 
prognosis for patients with metastatic RCC. (5,6) Nevertheless, their therapeutic effects are still 
limited and their side-effects remain difficult issues that often cause treatment failure or require 
additional therapeutic management. (7) Therefore, the identification of a new therapeutic target 
that will contribute to the development of a more effective and less toxic treatment strategy for 
metastatic RCC treatment is also needed. 
For the above-described needs for RCC treatment, large neutral amino acid 
transporter 1 (LAT1, SLC7A5) has the potential to offer promising opportunities. LAT1 is a 
member of the L-type amino acid transporter family (other members being LAT2 [SLC7A8], 
LAT3 [SLC43A1], and LAT4 [SLC43A2]). (8,9) It has been shown that LAT1 is abundantly 
expressed in various types of cancer, including non-small cell lung cancer, breast cancer, biliary 
tract cancer, pancreatic cancer, and prostate cancer, in a cancer-associated manner. (10-15) Cancer 
cells require essential amino acids for growth and invasion, and LAT1 serves as a primary Na+-
independent transport system for uptake of neutral amino acids including several essential 
amino acids. (16) Furthermore, LAT1-mediated leucine uptake is closely linked to the 
mammalian target of rapamycin (mTOR) signaling pathway, which plays a key role in cell 
growth, transcription, and translation. (17,18) Consistently, several studies have shown an 
association of higher LAT1 expression level with poorer prognosis in various types of cancer. 
(12-15) 
JPH203 (KYT0353) has been developed as a first-in-class LAT1-specific inhibitor. 
(19) JPH203 is a tyrosine analog and thus competitively inhibits LAT1 transporter functions in 
several types of cancer cells to attenuate their migration/invasion activities and induce 
apoptosis, which has been thought to be associated with inactivation of the mTOR signaling 
pathway. (20-22) Moreover, JPH203 has shown significant inhibitory effects on the growth of 
xenografted human colon and thyroid cancer cells in mice, (23,24) and its efficacy is currently 
being evaluated in a clinical trial of patients with several types of cancer. (25)  
Based on the above-described findings, LAT1 seems to be a promising prognostic 
biomarker as well as a molecular target in RCC clinical settings. However, the LAT1 expression 
profiles in RCC patients and the effects of JPH203 on RCC cells have not been characterized. 
Therefore, in this study, with the aim of clarifying the roles of LAT1 in RCC prognosis and 
treatment, we retrospectively investigated the LAT1 expression profile and its association with 
clinical factors in RCC tissues. The effects of JPH203 were also examined using two RCC cell 
lines. 
Results 
Characterization of the LAT1 expression profile in renal cell carcinoma 
In order to characterize the LAT1 expression profile in RCC, we first performed 
immunohistochemistry using patients’ tissue sections (n = 92). Representative staining pictures 
of RCC and normal kidney tissues are shown in Fig. 1 and Fig. S1, respectively. The results 
showed that 90 patients (97.8%) were LAT1 expression-positive in their cancerous areas, and 
two patients were negative. The LAT1 staining appeared to be cancer-associated because LAT1 
expression in the adjacent normal areas was clearly limited to the proximal tubules, which is a 
typical LAT1 expression pattern in the human normal kidney as shown in the database (The 
Human Protein Atlas; https://www.proteinatlas.org).  
To investigate whether LAT1 expression levels were associated with 
clinicopathological factors, we classified the patients into two groups depending on the LAT1 
expression scores [S] in their RCC tissues. As shown in Fig. 1, one group was a high LAT1 
expression group consisting of 34 patients for whom [S] were 6 to 9 and the other group was a 
low LAT1 expression group consisting of 58 patients including two negative patients for whom 
[S] were 0 to 4. Then comparative analyses were conducted to determine relationships of LAT1 
expression levels with patients’ age, sex, disease stages, T stages, vascular invasion status, and 
grades. As shown in Table S1, a high LAT1 expression was correlated with vascular invasion 
status (P = 0.009) and T stage (P = 0.037).  
  
Associations of LAT1 expression with overall survival and progression-free survival in renal cell 
carcinoma 
Since LAT1 expression levels were often found in RCC with malignant phenotypes, 
we examined the associations LAT1 expression with OS and PFS of the patients. 
The Kaplan-Meier plots in Fig. 2 showed that OS in the high LAT1 expression group 
was shorter than that in the low LAT1 expression group (HR: 3.7, 95% CI: 1.3-10.6, P = 0.018). 
In addition, cause-specific postoperative survival curves for patients with [S] >3 and [S] 0-3 
(Fig. S2A), along with those with large (>30%) and small (0-30%) LAT1 expression area (Fig. 
S2B) are shown. These OS in the high LAT1 expression group were shorter than those in the 
low LAT1 expression group (HR: 3.4, 95% CI: 1.2-9.5, P = 0.041, and HR: 3.5, 95% CI: 
1.2-10.4, P = 0.025, respectively) 
Univariate analysis with the Cox proportional hazards model revealed that the LAT1 
score and the disease stage, pathological T stage, and histological grade were all significant 
determinants of OS (Table 1). In multivariate analysis, in addition to the disease stage, the LAT1 
score was identified as an independent factor associated with OS (HR: 4.5, 95% CI: 1.1-25.6, P 
= 0.035) (Table 1).  
Similarly, PFS in the high LAT1 expression group was shorter than that in the low 
LAT1 expression group in Kaplan-Meier analysis (HR: 3.9, 95% CI: 1.3-12.2, P = 0.014). When 
univariate analysis was performed, the LAT1 score as well as the disease stage and the 
histological grade were found to be significant determinants of PFS (Table 2). In multivariate 
analysis, the LAT1 score and the disease stage were identified as independent factor associated 
with PFS (HR: 3.7, 95% CI: 1.2-13.4, P = 0.018, and HR: 5.3, 95% CI: 1.8-17.8, P = 0.0033, 
respectively) (Table 2). 
Functional expression of LAT1 and inhibitory property of JPH203 against LAT1 function in 
renal cell carcinoma cells 
 The association found between LAT1 expression and malignant cancer phenotypes 
suggested that LAT1 has the potential to be a molecular target for RCC therapy, which has 
remained to be determined in RCC cells. Thus, we aimed to determine whether LAT1 inhibition 
causes suppression of RCC cells proliferation activity. 
First, the functional expression of LAT1 in two representative RCC cell lines, Caki-1 
and ACHN cells was examined. Additionally, human embryonic kidney 293 (HEK293) cells 
were used as comparison purpose. The results of qPCR showed that LAT1 mRNA was clearly 
expressed in the two cell lines, the levels of which were comparable (Fig. 3A). LAT1 expression 
was also confirmed by Western blot analysis in these cells (Fig. 3B). In addition to LAT1, the 
mRNA expression of other LAT family members (LAT2, LAT3, and LAT4) was also detected in 
the cells. However, their levels were substantially lower than that of LAT1, indicating that LAT1 
is exclusively expressed in Caki-1 and ACHN cells. In contrast, LAT1 mRNA expression was 
quite low in HEK293 cells. 
We then tested the effects of JPH203, a selective LAT1 inhibitor, on the system L 
amino acid transport activity in these cells (Fig. 4). The results of transport assays showed that 
JPH203 (10 µM) clearly inhibited leucine uptake activities in these cells to decrease their levels 
to 79% (Caki-1), 68% (ACHN), and 49% (HEK293) of that of the control cells (DMSO-treated 
cells), respectively. 
Inhibition of growth, migration and invasion inhibition of renal cell carcinoma cells by JPH203 
treatment 
Since functional LAT1 expression and inhibitory effects of JPH203 on its activity 
were validated in RCC cells, we assessed the effects of JPH203 on the proliferation activities of 
these cells. 
When the cells were treated with JPH203, RCC cells viability were significantly 
reduced in a dose-dependent manner (Fig. 5A). The IC50 values of Caki-1 and ACHN cells were 
2.5 and 2.7 µM, respectively, and JPH203 thus showed comparable growth inhibition potencies 
against the two cell types. In contrast, JPH203 treatment did not show any growth inhibitory 
effects on HEK293 cells. 
We also tested the effects of JPH203 on the migration (Fig. 5B) and invasion (Fig. 
5C) abilities of these cells. The results showed that the migration and invasion rates of ACHN 
cells treated with JPH203 (10 or 30 µM) were significantly lower than those of the control 
(DMSO-treated) cells (0.7-fold and 0.5-fold lower for migration and 0.4-fold and 0.3-fold lower 
for invasion, respectively). Similar results were also obtained using Caki-1 cells. 
Collectively, the results indicated that JPH203 possessed inhibitory effects on cell 
proliferation, migration and invasion activities on the RCC cells. 
Inhibition of the mTOR pathway in RCC cells by JPH203 
It has been shown that LAT1-mediated leucine uptake stimulates cancer cell 
proliferation activities through activating the mTOR signaling pathway, which has been 
considered as a reason why LAT1 functional inhibition reduce cell viability in various cancer 
cells. (18) Therefore, we presumed that inhibition of the mTOR signaling pathway was also 
associated with reduction of cell viability of JPH203 in RCC cells. 
To examine this possibility, Caki-1 cells were treated with JPH203 (10 µM) for 24, 
48, and 72 h to see the phosphorylation status of mTOR and its downstream proteins. As a 
result, while not so remarkable in mTOR, JPH203 treatment substantially reduced 
phosphorylation levels of p70S6K and 4E-BP1, indicating that JPH203 inhibited the mTOR 
signaling pathway in Caki-1 cells (Fig. 6). Similar results were also obtained using ACHN cells 
(Fig. S3). 
To investigate whether inhibition of the mTOR pathway could be involved in 
pharmacological actions of JPH203, cells were treated with rapamycin (10 or 30 nM) and 
JPH203 (10 or 30 µM) separately or together for 72 h. Their cell viability of rapamycin-treated 
cells was significantly reduced, but it did not show any additive or synergistic effects on 
JPH203 (Fig.S4). 
Discussion 
In this study, we clearly showed that LAT1 is overexpressed in RCC in a cancer-
associated manner and that inhibition of LAT1 function prevents progression of two RCC cell 
types. These findings are important advances for future application of LAT1 to RCC diagnosis 
and treatment. 
 Regarding the diagnostic property of LAT1, its very high expression frequency in 
patients with RCC, 97% in 92 patients, is noteworthy. While comparable to that found in gastric 
cancer (92%, n = 64), (26) the value is remarkably higher than the values for prostate cancer 
(24%, n = 54), (27) lung cancer (36%, n = 160) (28) and ovarian cancer (39%, n = 142). (29) 
Furthermore, the LAT1 detection frequency is also superior to the detection frequency of other 
genes that are overexpressed in RCC. For example, it has been reported that the PD-L1 
expression-positive rate is 36% (n = 453), (30) and those of vimentin, survivin, and p53 have 
been reported to be 30% to 80%. (31,32)   
 In addition, it should be pointed out that the association of LAT1 expression levels 
with the OS and the PFS in our patients can add further value to LAT1 as a RCC biomarker 
because identification of a clinically valuable prognostic marker has been needed for RCC. 
Several proteins have been investigated as potential prognosis biomarkers for RCC. However, 
their prognostic powers do not seem to be sufficient for use in clinical practice. The mTOR 
signaling pathway is often activated in RCC, and higher levels of the phosphorylation status of 
the pathway proteins (mTOR, 4EBP and S6K) have been reported to be associated with poorer 
prognosis in ccRCC patients (HR = 0.9, 1.5 and 1.5 for OS and HR = 0.9, 2.7 and 2.6 for PFS, 
respectively). (33) The expression level of PD-L1 has also been reported to be associated with 
cancer-specific mortality in RCC patients (HR = 2.0). (30) However, in comparison to those 
proteins, LAT1 exhibits high prognostic power (HR = 3.5 and 4.4 for OS and PFS, respectively) 
at least in our patients. 
 Collectively, our results strongly suggest that, in line with its high expression 
frequency, LAT1 is one of the most promising prognostic markers for RCC patients. Thus, it is 
possible that high levels of LAT1 expression in surgical specimens would indicate the need to 
follow up the patient closely with frequent imaging in order to take precautions against 
recurrence and to start treatment as soon as possible Nevertheless, we have to admit that the 
number of the patients examined in this study is limited, and thus concrete establishment of 
LAT1 as an RCC prognostic biomarker should await further larger-scale investigations. In 
addition, we need to explore a way to improve its diagnostic power, possibly by using it in 
combination with other marker proteins. It has been reported that simultaneous high levels of 
detection of five different proteins (mTOR, AKT, PTEN, PI3K, and p-4EBP) are more clearly 
associated with poor prognosis in RCC (HR = 4.8 for OS). (34) Therefore, it will be worth 
seeking the best partners for LAT1 to mutually enhance their biomarker potentials in future 
studies. 
 Aside from its biomarker potential, our results also indicate the possibility that 
JPH203-mediated functional LAT1 inhibition is a promising approach for treatment of 
recurrence of RCC. Of note, since a high expression level of LAT1 is associated with poor 
prognosis in RCC, an LAT1-targeting anti-cancer approach has the potential to be a key 
therapeutic option to for malignant RCC. 
The effects of JPH203 have been tested in various types of solid cancer, but this 
report is the first report for RCC cells. It should be mentioned that the efficacy levels in RCC 
cells (IC50 = 2.5 and 2.7 µM) are higher than those reported so far in other cancer types (2.3 to 
41.7 µM). (24,35) Therefore, it can be assumed that RCC is a preferable target for JPH203-
mediated therapy. Regarding its mechanisms, it has been considered that JPH203 blocks LAT1-
mediated essential amino acid uptake, not only depleting the materials for protein synthesis but 
also inactivating the mTOR signaling pathway. (15.20.23.36.37) The suppression of phosphorylation 
levels in mTOR downstream proteins has been validated in our JPH203-treated RCC cells, 
suggesting that similar mechanisms of action underlie the effects of JPH203. Likewise, lack of 
additional effects of rapamycin on JPH203 in this study implies that these two agents share the 
same cellular pathways to exert their pharmacological actions. 
Furthermore, considering that LAT1 is overexpressed in cancer cells, LAT1-targeting 
RCC therapy may offer favorable tolerability. This may be too speculative at present, but in 
support of this, preliminary results of the first-in-human clinical trials (n = 17, colon, pancreas, 
bile duct, esophagus, and breast cancer patients) show not only long-term survival for more than 
two years in a patient with bile duct cancer but also the occurrence of grade 3 or higher side 
effects (liver damage) in only 12% of the patients. (25) Since side effects have often caused dose 
delays or reductions of molecularly targeted therapeutics or immune checkpoint inhibitors in 
RCC patients, it will be important to focus on the safety potential of JPH203 in future studies.  
In conclusion, we showed that LAT1 is overexpressed in RCC at a high frequency 
and that there is an unequivocal association of higher levels of LAT1 expression with poorer 
prognosis of RCC. We also clarified that functional LAT1 inhibition by JPH203 significantly 
reduce the proliferation activities of RCC cells. Therefore, LAT1 holds the great potentials not 
only as a prognosis biomarker but also as a therapeutic target in RCC clinical settings. To 
further advance our research, we are currently planning to conduct a phase 2 clinical trial for 
patients with RCC. 
Methods 
Clinical RCC specimens 
A total of 92 clinical specimens were obtained from clear cell RCC patients who had 
undergone nephrectomy or partial nephrectomy at Chiba University Hospital (Chiba, Japan) 
between April 2007 and March 2011. All of the patients provided the signed informed consent, 
and the study protocol was approved by the Institutional Review Board of Chiba University 
(approval no. 484). All experiments were performed in accordance with relevant guidelines and 
regulations as described by our institution. Information on patients is summarized in Table S2. 
Immunohistochemistry 
Immunohistochemical staining for detection of LAT1 was performed on formalin-
fixed and paraffin-embedded tissue sections (4 µm in thickness) using a mouse anti-LAT1 
monoclonal antibody (clone no. 4D9; Transgenic, Kumamoto, Japan). The detailed 
experimental methods were reported previously. (38)  
Scoring of immunohistochemical staining  
Immunoreactivity for LAT1 was evaluated according to Sinicrope’s method (39) with 
minor modifications as reported previously. (26) Briefly, LAT1 expression score [S] was 
determined on the basis of both the staining intensity level [I] at the carcinoma cell membranes 
and the staining area level [A], which represents a percentage of the whole carcinoma area, 
relative to the total section area. [I] was classified as follows: 0, no staining; 1, weakly; 2, 
moderate; and 3, intense. [A] was classified as follows: 0, none; 1, 1–10% (focal); 2, 11–30% 
(partial); and 3, >30% (diffuse). [S] for each patient was obtained by multiplying [I] by [A]. 
Scoring calculations were performed by two independent investigators (J.M. and K.H.) who 
were blinded to each patients’ clinical status. Based on [S], patients were divided into high and 
low LAT1 expression groups ([S] 0–4 and [S] 6–9, respectively).  
The cut-off value used in Fig. 2 was determined using the Receiver Operating 
Characteristic (ROC) curve. In addition, other cut-off value [S] 4 or staining area >30%, which 
were used in Fig. S2, were determined using the respective median value. 
Cell culture  
Human RCC cell lines, Caki-1 and ACHN, were obtained from the Cell Resource 
Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku 
University (Miyagi, Japan). Both cell types were cultured in RPMI-1640 medium supplemented 
with 10% fetal bovine serum and penicillin-streptomycin. HEK293 cells was cultured in 
DMEM medium supplemented with 10% fetal bovine serum and penicillin-streptomycin. These 
cells were maintained in an incubator with a humidified atmosphere of 95% air and 5% CO2 at 
37°C.  
Quantitative PCR (qPCR) 
The mRNA expression levels of LAT1, LAT2, LAT3, and LAT4 in RCC cells and 
HEK293 cells were quantified by qPCR. The β-actin mRNA levels were also quantified for use 
as a normalization control. Experiments were performed according to a protocol reported 
previously. (38) Information on the specific primers is shown in Table S3. 
Cell viability assay  
 Inhibitory effects of JPH203 (MedKoo, Morrisville, NC) on the proliferation 
activities of Caki-1, ACTN and HEK293 cells were evaluated using a WST-8 kit (Nacalai 
Tesque, Kyoto, Japan) according to the manufacturer’s protocol. The experiment was performed 
as previously reported. (35) IC50, which is the concentration at which the cell viability is reduced 
by half, was calculated using GraphPad Prism 7J (GraphPad Software, La Jolla, CA). Similarly, 
inhibitory effects of JPH203 and rapamycin (FUJIFILM Wako Pure Chemical Corporation, 
Osaka, Japan) on the proliferation activities of Caki-1 and ACTN cells were also evaluated 
using a WST-8 kit. The cells were seeded onto 96-well plates (0.5 × 104 cells/well) and cultured 
with JPH203 (10 or 30 µM), rapamycin (10 or 30 nM), or DMSO (0.5%, a vehicle control), for 
three days, after which a viability assay was performed. 
Migration and invasion 
Cell migration and invasion were assessed using Corning Falcon Cell Culture Inserts 
(Thermo Fisher Scientific, Waltham, MA) and Corning BioCoat Matrigel Invasion Chamber 
(Thermo Fisher Scientific), respectively. The essential parts of the experiments were described 
previously. (40) The cells were seeded at the upper chamber of a transwell insert at 1 × 105 cells/
well and then incubated for 48 hours with serum-free RPMI1640 medium containing JPH203 
(10 and 30 µM) or dimethyl sulfoxide (DMSO) for experimental and control groups, 
respectively. The numbers of cells that had migrated or invaded in five random microscopic 
fields, which were randomly selected, were counted using Image J version 1.8.0. (National 
Institutes of Health, Bethesda, MD). 
L-leucine uptake assays 
LAT1 function and the ability of JPH203 to inhibit LAT1 function in RCC cells and 
HEK293 cells were examined by transport assays using L-leucine (leucine) (containing 
[14C]leucine at 0.1 mCi/mL) (PerkinElmer, Boston, MA) as a substrate. These cells were seeded 
onto 24-well plates (0.5 × 105 cells/well) and cultured for two days, after which a transport 
assay was performed. The experiment was performed as previously reported. (35) 
Western blot analysis  
The cells were dissolved in a sample buffer (25% glycerol, 1% sodium dodecyl 
sulfate [SDS], 62.5 mM Tris-Cl, 10 mM dithiothreitol) and pre-incubated at 95°C for 5 min. 
Aliquots of samples containing 20 µg protein were applied to 10% SDS-polyacrylamide 
electrophoresis (PAGE) and then transferred onto PVDF membranes. The membranes were 
incubated at room temperature for 1 hour in TBS-T (10 mM Tris–HCl, 100 mM NaCl, 0.1% 
Tween-20, pH 7.5) with 5% skim milk (for LAT1 and β-actin) or Blocking One-P (Nacalai 
Tesque) (for mTOR, phosphorylated mTOR [p-mTOR], 4E-binding protein 1 [4E-BP-1], p-4E-
BP-1, ribosomal protein S6kinase beta-1 [p70S6K], and p-p70S6K), after which they were 
incubated with primary antibodies at 4°C overnight. After washed with TBS-T, the blots were 
incubated with an HRP-conjugated anti-rabbit IgG antibody for 1 hour at room temperature. 
Information on the antibodies used in this study is given in Table S4. 
 Signals were generated by Clarity MAX Western ECL Substrate (Bio-Rad 
Laboratories, Hercules, CA) and visualized with LAS-4000 mini (Fujifilm, Tokyo, Japan), of 
which intensities were quantified using the Image J version 1.8.0. 
Statistical analysis 
The Kaplan-Meier method and the log-rank test were used to analyze survival 
differences. Univariate and multivariate Cox proportional models were used in statistical 
analyses for association of clinical factors with overall survival (OS) and progression-free 
survival (PFS). OS was determined using the period from the operation to death for each 
patient. PFS was defined as the period from the operation to the first disease progression or 
death. The Wilcoxon signed-rank test and chi-square test were used to assess associations of 
LAT1 expression with clinical factors. The unpaired Student's t-test was used for investigating 
differences between two groups. Statistical calculations were done with JMP Pro, version 
13.0.0. (SAS Institute, Cary, NC). P values below 0.05 indicate statistically significant 
differences. 
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Figure legends 
Fig. 1. Representative staining pictures showing LAT1 expression in RCC tissues 
LAT1 expression in RCC tissues was analyzed by immunohistochemistry. A 
representative LAT1 immunostaining picture in the low LAT1 expression group is shown at 
100-times magnification (panel A) and 400-times magnification (panel B). Similarly, a 
representative LAT1 immunostaining picture in the high LAT1 expression group is shown at 
100-times magnification (panel C) and 400-times magnification (panel D).  
Fig. 2. Postoperative survival of RCC patients categorized by LAT1 expression 
Cause-specific postoperative survival curves (A, overall survival [OS] and B, 
progression free-survival [PFS]) for patients with high and low LAT1 expression levels are 
shown. Analysis was performed the using Kaplan-Meier method with the log-rank test.  
Fig. 3. Quantification of mRNA expression levels of LAT family members and detection of 
LAT1 protein expression in RCC cells 
(A) LAT1, LAT2, LAT3, and LAT4 mRNA expression levels were analyzed by qPCR 
in Caki-1, ACHN and HEK293 cells. Experiments were performed at least three times, each 
performed in duplicate. The mRNA expression levels were normalized to those of β-actin, and 
data are expressed as means with S.E.M. (B) LAT1 protein expression was analyzed by Western 
blotting in Caki-1, ACHN and HEK293 cells. β-actin was used as a loading control. 
Representative results from three independent experiments are shown. 
Fig. 4. Inhibition of [14C]-leucine uptake by JPH203 in RCC cells 
The Na+-independent [14C]-leucine uptake activities (1 µM leucine containing [14C]-
leucine at 0.1 mCi/mL) of Caki-1, ACHN and HEK293 cells were determined in the presence 
(+) and absence (-) of JPH203 (10 µM). Determinations were performed three times, each 
performed in triplicate. Each value represents the mean with S.E.M. *, P<0.05 (unpaired 
Student’s t-test). 
Fig. 5. Effects of JPH203 on the viability, migration and invasion activities of RCC cells  
(A) Caki-1, ACHN and HEK293 cells were treated with various concentrations 
(0.01, 0.1, 1, 3, 10, 30, and 50 µM) of JPH203 for 96 h. The cell viabilities were determined by 
WST-8 assays, and viability curves are presented as a percentage of the control value, which 
was obtained from cells treated with DMSO (0.5%). Data are expressed as means with S.E.M. 
The IC50 values for each cell line were calculated using GraphPad Prism 7J. The experiments 
were repeated three times, each performed in triplicate. 
 (B) Transwell chamber migration assays and (C) matrigel invasion assays were used 
to evaluate the migratory and invasive capabilities of RCC cells following treatment with 
JPH203 (10 or 30 µM) or DMSO (0.5%) for 48 h. The numbers of cells in five random 
microscopic fields were counted. Representative images from three independent experiments 
are shown. Each bar represents the mean with S.E.M. *, P<0.05; **, P<0.01 (unpaired Student’s 
t-test). 
Fig. 6. Effects of JPH203 on phosphorylation status of molecules belonging to the mTOR 
signaling pathway in Cak-1i cells 
(A) Caki-1 cells were incubated with normal growth medium in the presence of 
JPH203 (10 µM) for 24 h, 48 h, and 72 h, or DMSO (0.5%, a vehicle control) for 72 h. Whole 
cellular proteins were extracted and the phosphorylation status of mTOR, p70S6K, and 4E-BP1 
was analyzed. β-actin was used as a loading control. Their total protein levels were also 
examined for references. Representative images from three independent experiments are shown. 
(B) The signal intensities were quantified using the Image J version 1.8. 
Table 1. Univariable and multivariable cox hazard regression models for OS survival in 
patients with RCC. 
　 　 　 Univariate Analysis 　 Multivariate Analysis
Clinical 
Factor Cut off 　 HR 95% CI P value 　 HR 95% CI P value
Age 70 2.4 0.72 - 7.31 0.14
Sex Male / Female 0.8 0.25 - 2.8 0.66
Disease stage 3 7.5 2.57 - 22.78 0.0003 12.3
1.88 - 
74.8 0.0096
T stage 2 4.9 1.6 - 14.09 0.0067 2.8
0.41 - 
16.09 0.27
Vascular 
invasion 2 2.9
0.79 - 
8.66 0.1
Grade 2 3.7 1.00 - 23.6 0.05 1.5
0.30 - 
11.12 0.61
LAT1 scare High / Low 　 3.5 1.15 - 12.75 0.026 　 4.5
1.07 - 
25.55 0.035
Table 2. Univariable and multivariable cox hazard regression models for PFS in patients 
with RCC. 
　 　 　 　 　 　 　 　 　 　
　 　 Univariate Analysis Multivariate Analysis
Clinical 
Factor Cut off 　 HR 95% CI P value 　 HR 95% CI P value
Age 70 1.4 0.37 - 4.01 0.61
Sex Male / Female 0.6
0.21 - 
1.93 0.37
Disease stage 3 7.8 2.78 - 22.33 0.0002 5.3
1.76 - 
17.76 0.0033
T stage 2 2.9 0.80 - 8.56 0.096
Vascular 
invasion 2 2.5
0.69 - 
7.33 0.15
Grade 2 4.2 1.16 - 27.02 0.026 2.0
0.42 - 
13.79 0.40
LAT1 scare High / Low 4.4 1.50 - 15.9 0.0062 3.7
1.24 - 
13.35 0.018
　 　 　 　 　 　 　 　 　 　
 
 
  
 
 
Table S1. Clinical factors associated with LAT1 expression levels in patients with 
RCC. 
　 　 　 　
Clinical Factor Low LAT1 (n=34)
High LAT1 
(n=58) P value
Age (AV± SD) 58.6 ± 11.5 62.5 ± 13.4 0.133
Sex (% male) 80.7% 77.1% 0.562
Disease stage (% of stage 3 or greater) 12.2% 20% 0.172
T stage (% of pT2 or greater) 7% 22.8% 0.037
Vascular invasion 5.40% 25% 0.009
Grade (% of grade 2 or greater) 63% 67% 0.428
　 　 　 　
Table S2. Patients’ characteristics 
　 　
Patients characteristics number
Age (AV± SD) 58.6 ± 11.5
Sex  male 73
female 19
Disease stage 1 75
2 3
3 6
4 8
T stage 1 79
2 4
3 8
4 1
Vascular invasion 12
Grade 1 33
2 51
3 8
Total nephrectomy 58
Partial nephrectomy 36
LAT1 score 0 2
1 2
2 8
3 34
4 12
6 28
9 6
Follow-up duration (Month, AV± SD) 77.4 ± 40.5
Table S3. Primers 
Table S4. Antibodies 
mRNA 　 Primer (5’ > 3’)
LAT1 forward TGTACGTGCTGACCAACCTG
reverse ATGACGCCCAGGTGATAGTTC
LAT2 forward CACGGTTGCTGGACAGATAG
reverse GGGAACAGCAGGTTGATCTT
LAT3 forward ATGGACTGGCGGATCAAGG
reverse TCTTGCAGTAGCGTGGTCTGATG
LAT4 forward GGTGGACAAGTTTCTGCTGAGTG
reverse CAGCTGTATGAGGATGCGGTGTA
β-actin forward CCAACCGCGAGAAGATGA
　 reverse CCAGAGGCGTACAGGGATAG
Antibody Supplier Dilution
Mouse anti-LAT1 antibody Trans Genic Inc. 1:200
Rabbit anti-β-actin antibody Cell Signaling Technology 1:1000
Rabbit anti-mTOR antibody Cell Signaling Technology 1:1000
Rabbit anti-p-mTOR antibody Cell Signaling Technology 1:1000
Rabbit anti-4E-BP1 antibody Cell Signaling Technology 1:1000
Rabbit anti-p-4E-BP-1 antibody Cell Signaling Technology 1:1000
Rabbit anti-p70S6K antibody Thermo Fisher Scientific 1:1000
Rabbit anti-p-p70S6K antibody Cell Signaling Technology 1:1000
ECL-anti-rabbit IgG, horseradish peroxidase 
linked whole antibody from donkey GE Healthcare UK Ltd 1:10000
ECL-anti-mouse IgG, horseradish peroxidase 
linked whole antibody from sheep GE Healthcare UK Ltd 1:20000
Fig. S1. Representative staining pictures showing LAT1 expression in normal kidney 
tissues 
 LAT1 expression in normal kidney tissues was analyzed by immunohistochemistry 
(A, ×100 B, ×400). Representative staining images are shown. 
 
Fig. S2. Postoperative survival of RCC patients categorized by various cutoffs of LAT1 
expression 
 Cause-specific postoperative overall survival curves for patients (A) with [S] 4-9 and 
[S] 0-3, (B) with >30% of LAT1 expression area and 0-30% of LAT1 expression area are 
shown. Analysis was performed the using Kaplan-Meier method with the log-rank test. 
 
Fig. S3. Effects of JPH203 on phosphorylation status of molecules belonging to the mTOR 
signaling pathway in ACHN cells 
(A) ACHN cells were incubated with normal growth medium in the presence of JPH203 (10 
µM) for 24 h, 48 h, and 72 h, or DMSO (0.5%, a vehicle control) for 72 h. Whole cellular 
proteins were extracted and the phosphorylation status of mTOR, p70S6K, and 4E-BP1 was 
analyzed. β-actin was used as a loading control. Their total protein levels were also examined 
for references. Representative images from three independent experiments are shown. (B) The 
signal intensities were quantified using the Image J version 1.8.0. 
 
Fig. S4. Effects of rapamycin treated with JPH203 on the viability of RCC cells 
 Caki-1 and ACHN cells were treated with rapamycin (10 or 30 nM or absence) and 
JPH203 (10 or 30 µM) or DMSO. The cell viabilities were determined by WST-8 assays, and 
viability bar graphs are presented as a percentage of the control value, which was obtained from 
cells treated with DMSO (0.5%). The experiments were repeated three times, each performed in 
triplicate. Each bar represents the mean with S.E.M. *, P<0.05; n.s. not significant (unpaired 
Student’s t-test). 
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